Clinical Investigation of Infections Due to Leishmanial Parasites

Status Completed

Clinical Trial Summary

Mechanisms of host immune response to intracellular protozoa will be investigated in patients with naturally acquired infection employing a variety of in-vitro techniques. Both non-specific and antigen-specific humoral and cellular immune responses will be assessed. Parasites will be isolated from patients, cultivated in-vitro, and characterized. Responses to chemotherapy will be assessed parasitologically, immunologically and clinically.

Clinical Trial Description

The main purpose of this protocol is to permit us to see patients who are referred to us for diagnosis and treatment of known or suspected leishmaniasis (from the Peace Corps, Smithsonian Institution, tourists, etc.). In the process of working up these patients, we sometimes encounter parasite isolates that are useful for research. We also can perform tests of cell-mediated immune function to evaluate how patients are responding to therapy. In addition, the protocol permits us to observe therapeutic responses to other drugs besides pentavalent antimony, if necessary. ;

Study Design

N/A

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001169
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	December 1979
Completion date	February 2001

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03641339` - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans	N/A
Completed	`NCT04504435` - Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants	Phase 1
Completed	`NCT00004755` - Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil	Phase 2
Completed	`NCT00657618` - Use of Sodium Stibogluconate as a Treatment for Leishmaniasis	Phase 1/Phase 2
Completed	`NCT04512742` - A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies	N/A
Recruiting	`NCT00344188` - Diagnosis and Treatment of Leishmania Infections
Active, not recruiting	`NCT03009422` - Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.	N/A
Recruiting	`NCT05449717` - Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
Recruiting	`NCT06307171` - Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers	N/A
Completed	`NCT01751048` - LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine	Phase 1
Terminated	`NCT06124144` - Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults	Phase 1
Completed	`NCT00662012` - Sodium Stibogluconate Treatment of Leishmaniasis	Phase 2
Completed	`NCT03993093` - Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Recruiting	`NCT03784248` - Mediterranean Visceral Leishmaniasis With Leishmania Infantum
Withdrawn	`NCT02429505` - Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Completed	`NCT01377974` - Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis	Phase 2
Completed	`NCT02656797` - Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis	Phase 2
Completed	`NCT01484548` - Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers	Phase 1
Completed	`NCT01300975` - Intralesional Antimony for Bolivian Cutaneous Leishmaniasis	Phase 2
Completed	`NCT03294161` - Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis	Phase 2